References
- Bagshaw M D, Gordon R R, Rickard S K. Radiotherapy of prostatic carcinoma: long- or short-term efficacy. Urology 1985; 17–25, (XXV Suppl)
- Damber J-E, Bergh A, Landstrom M, Tomic R. Treatment of rat prostatic adenocarcinoma with medroxyprogesterone acetate (MPA): effects on growth and morphology. J Urol 1991; 145: 1283–1287
- Esposti P L. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. Scand J Urol Nephrol 1971; 5: 199–209
- Franzen S, Giertz G, Zajicek J. Cytolgoical diagnosis of prostatic tumours by transrectal aspitation biopsy: a preliminary report. Br J Urol 1960; 32: 193–196
- Grayhack J T, Keeler T C, Koslowski J M. Carcinoma of the prostate. Hormonal therapy. Cancer 1987; 589–601, (60 Suppl)
- Johansson J-E, Andersson S-O, Holmberg L. High-dose medroxyprogesterone acetate versus estramustine in therapy-resistant prostatic cancer: a randomized study. Br J Urol 1991; 68: 67–73
- Kurth K H, Altwein J E, Skoluda D, Hohenfellner R. Follow-up of irradiated prostatic carcinoma by aspiration biopsy. J Urol 1977; 117: 615–617
- Muntzing J, Kirdani R Y, Saroff J, et al. Estracyt on R-3327 rat prostatic carcinoma. Urology 1977; 10: 439–445
- Pardige W M. Transport of protein-bound hormones in tissues in vivo. Endocr Rev 1981; 2: 103–123
- Paulson D F. Radiotherapy versus surgery for localized prostatic cancer. Urol Clin North Am 1987; 14: 675–684
- Pavone-Macaluso M, de Voogt H J, Viggiano G, et al. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer. Final analysis of a randomized phase HI trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol 1986; 136: 624–631
- Tomic R, Bergman B, Hietala S-O, Ångström T. Prognostic significance of transrectal fine-needle aspiration biopsy findings after orchiectomy for carcinoma of the prostate. Eur Urol 1985; 11: 378–381
- Tomic R, Ljungberg B, Damber J-E. Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma. Scand J Urol Nephrol 1988; 22: 15–18